Akero Therapeutics Inc (AKRO) Stock Analysis

Akero Therapeutics Inc (AKRO) is a publicly traded company in the HEALTHCARE sector. It trades at $54.65. This page summarizes the public market data, fundamentals, and frequently asked questions for AKRO, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

About Akero Therapeutics Inc

Akero Therapeutics, Inc. is a biotechnology firm based in South San Francisco, California, dedicated to pioneering innovative therapies for nonalcoholic steatohepatitis (NASH), a prevalent liver disease associated with cardiometabolic health issues. Utilizing its proprietary drug development platform, the company aims to restore metabolic balance and improve patient outcomes, positioning itself as a leader in addressing the unmet needs of individuals afflicted by metabolic disorders. Akero's ...

GNG Research Analysis

GNG Research scores Akero Therapeutics Inc (AKRO) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for AKRO.

Frequently Asked Questions

Does AKRO pay dividends?

Akero Therapeutics Inc (AKRO) does not currently pay a regular dividend.